Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D (ON) Inhibitor
Merck has acquired exclusive global rights to SPR2015 from SciBrunch under a deal that includes an upfront payment of $400 million and has a total potential aggregate value of $2.13 billion. The transaction has closed and Merck will record a pre-tax charge of $400 million in the third quarter of 2026. SPR2015 is described as a preclinical oral KRAS G12D (ON) inhibitor with reported nanomolar antiproliferative activity and in vivo antitumor efficacy in CDX/PDX models.
Deal terms and financials
Merck and SciBrunch entered an exclusive global license agreement granting Merck rights to develop, manufacture and commercialize SPR2015 worldwide. SciBrunch will receive an upfront payment of $400 million and is eligible for additional milestone payments; the total potential aggregate value of the transaction, including the upfront payment, is $2.13 billion. The release states the transaction has closed and that Merck will record a pre-tax charge of $400 million, or approximately $0.13 per share, to be included in GAAP and non-GAAP results in the third quarter of 2026. BofA Securities acted as exclusive financial advisor to SciBrunch.
Sources: S1
About SPR2015
Merck describes SPR2015 as a potent and selective novel investigational preclinical molecular glue KRAS G12D (ON) inhibitor. The company reports that SPR2015 has demonstrated nanomolar antiproliferative activities in various KRAS G12D-mutant cell lines with selectivity over KRAS wildtype cells, and that it showed antitumor efficacy as a monotherapy across multiple in vivo cell-derived and patient-derived xenograft (CDX/PDX) models, as reported in preclinical data presented at the 2026 AACR Annual Meeting.
Sources: S1
Company statements
Merck framed the acquisition as complementary to its precision targeted pipeline and cited the therapeutic potential of targeting the KRAS pathway. SciBrunch described the agreement as validation of its R&D platform and expressed that Merck will take SPR2015 forward.
Sources: S1
Why this may matter (inference)
Inference: The agreement transfers global development and commercialization responsibility for a preclinical KRAS G12D (ON) program from a small biotech to an established pharmaceutical company, which could affect the program's resource base and regulatory pathway planning. Inference: The announced upfront and potential milestone structure signals the parties see commercial and development opportunity across multiple indications referenced in the release.
Sources: S1
What remains uncertain
- All technical, preclinical and clinical activity summaries in the release are issuer statements from Merck and SciBrunch; they are not independent verification.
- SPR2015 is described as preclinical; no clinical trial results or regulatory approvals are reported in the supplied source.
- Milestone and commercial outcomes are conditional and forward-looking; the release contains a forward-looking statements disclaimer and identifies customary development and regulatory risks.
- Financial accounting guidance other than the stated third quarter of 2026 charge is not provided in the source; no additional GAAP or non-GAAP detail is included.